The Pharma ETF Battle: PPH vs. PJP ๐
The pharmaceutical sector has long been a favorite for investors seeking recession-resistant demand and steady dividend income. But when it comes to picking the right ETF wrapper, two names keep showing up on screens: VanEck's Pharmaceutical ETF (PPH) and Invesco's Pharmaceuticals ETF (PJP).
On the surface, they look similar. Dig deeper, and the differences in cost structure, concentration, and geographic exposure become impossible to ignore. Here's what matters as of late September 2026.
Winner vs. Loser: Two Very Different Playbooks ๐ฏ
The Winner for Income & Cost: PPH
PPH charges just 0.36% versus PJP's 0.58% โ a 22 basis point edge. More importantly, PPH pays a 2.0% dividend yield compared to PJP's 0.9%. For income-focused investors, that's not a rounding error; it's a structural advantage.
The Winner for Momentum: PJP
PJP posted a 41.0% 1-year return versus PPH's 31.0%. Its equal-weighting approach and U.S.-only focus gave it cleaner exposure to domestic pharma momentum. But that outperformance came with a higher fee and thinner payout.
The Concentration Question
PPH runs a top-heavy book: Eli Lilly at 20.82%, Merck at 13.36%, Novo Nordisk at 5.62%. PJP caps its top names near 5.5% each (Gilead, Pfizer, AbbVie). Concentration cuts both ways โ it amplifies winners and magnifies drawdowns.
Not surprisingly, the market is split on which fund deserves the crown. Here's how both sides are arguing it:
Head-to-Head Comparison ๐
| Metric | PJP (Invesco) | PPH (VanEck) |
|---|---|---|
| Expense Ratio | 0.58% | 0.36% โ |
| Dividend Yield | 0.9% | 2.0% โ |
| 1-Yr Return | 41.0% โ | 31.0% |
| AUM | $569.6M | $1.0B โ |
| Beta | 0.43 | 0.45 |
| Max Drawdown (5Y) | -17.5% โ | -20.3% |
| Holdings | 30 | 26 |
| Geographic Focus | U.S. only | Global (63.7% U.S.) |
| $1,000 Growth (5Y) | $1,722 โ | $1,677 |
Technical Read & Historical Context
From a technical perspective, PPH's heavy Lilly weighting means its chart often tracks LLY's momentum more than the broader pharma index โ a hidden single-stock risk. Historically, pharma ETFs that lean on a single mega-cap have shown amplified drawdowns during GLP-1 sentiment reversals, a pattern worth watching if Lilly's valuation compresses.
๐ In-Depth Fundamental Analysis
| Company | Share Price | P/E Ratio | P/B Ratio | ROE | Operating Margin (OPM) | Revenue Growth |
|---|---|---|---|---|---|---|
| ABBV (AbbVie) | $263 | 73.62 | -78.24 | 0.00% | 40.03% | 10.20% |
| GILD (Gilead) | $145 | 0.00 | 15.18 | -20.68% | 33.68% | 10.20% |
| LLY (Eli) | $1,143 | 38.31 | 30.07 | 102.29% | 54.22% | 47.70% |
| MRK (Merck) | $144 | 114.52 | 8.50 | 6.96% | -0.24% | 5.10% |
| NVO (Novo) | $37 | 9.40 | 4.92 | 59.81% | 42.54% | 2.10% |
| PFE (Pfizer,) | $28 | 36.58 | 1.86 | 5.01% | 27.88% | 2.60% |
The Verdict: It Depends on Your Mandate ๐งญ
Choose PPH if you want:
- Lower fees and double the dividend yield
- Global pharma exposure with U.S. dominance
- Better liquidity for active trading (larger AUM)
- A long-term buy-and-hold income vehicle
Choose PJP if you want:
- Pure U.S. pharma exposure
- Stronger recent momentum and backtested returns
- Balanced weighting (no single-stock blow-up risk)
Neither fund is a slam dunk. PPH wins on cost and income; PJP wins on recent performance and diversification. For most long-term investors, the fee and yield gap tilts the scale toward PPH โ but if you're chasing momentum, PJP has the receipts.
Risk note: Pharma ETFs remain exposed to drug pricing legislation, FDA decisions, and patent cliff cycles. Past performance never guarantees future results โ position sizing matters more than ticker selection.
